TEST:

Immunoscore®

These findings indicate that triple chromogenic immunohistochemistry combined with digital pathology is an applicable method for quantifying tumor intraepithelial CD8+ and stromal FOXP3+ cell densities, allowing for the determination of the CD8IE-FOXP3IS score. The CD8IE-FOXP3IS score shows strong prognostic value, which appears superior to overall CD3+ and CD8+ T cell density measurement.

P=N/A; N=100; Recruiting; Sponsor:Institut Sainte Catherine

This study found that CD8IM TILs might be a marker as good as the more complex IS for predicting CRC prognosis in non-metastatic CRC patients CD8IM should be further explored as a simple predictive biomarker of adjuvant therapy benefits to advance personalized medicine in early-stage CRC.

Preliminary results of the POCHI trial demonstrate a good safety profile and a high efficacy of Pembrolizumab combined to a standard regimen (CAPOX+bevacizumab). To our opinion the impressive ORR and DCR observed justify further evaluation in a randomized phase III trial dedicated to pMMR/MSS mCRC pts with a high immune infiltrate.

In this combined analysis of 2 adjuvant trials dedicated to stage III colon cancer patients, post-surgery ctDNA was found in 19.7% of them and was confirmed as a major independent prognostic marker. Immunoscore® was also confirmed as an independent prognostic marker in the 80.3% of patients that are ctDNA-.

Conclusions These preliminary results of the POCHI trial demonstrate a good safety profile and a high efficacy of Pembrolizumab combined to a standard therapeutic regimen. The impressive CR rate and DCR observed justify further evaluation of the quadruplet treatment combination in a randomized phase III trial dedicated pMMR/MSS mCRC pts with a high immune infiltrate.

This study found no association between immune cell score and survival. These results indicate that immune cell score may not serve as a prognostic tool in ccRCC.

CAF-PD-1+CD8+ T cell interactions were absent from low IS tumors. Thus, CAF-PD-1+CD8+ T cell interactions are important in CRC patients with high IS, and these cellular interactions require further investigation.

We achieved increasingly precise and biologically relevant biomarkers by using data-driven CD3/CD8 density cutoffs and ratios, while controlling for important clinicopathologic and molecular variables in CRC. Independent validation and inclusion of other immune or stromal cell types will bring these findings closer to clinical utility in CRC.

Methods Patients with MSS mCRC who have progressed on 2-3 lines of prior chemotherapy regimen received PolyPEPI1018 (1.2 mg, sc) and atezolizumab (1,200 mg, iv) Q3W. PolyPEPI1018 induced immunological responses at both peripheral and tumor level, converted "cold" tumor into "hot", although to date no responses per RECIST have been noted. The study is on-going.

Total 29 patients had validated results from Immunoscore® and were included in this analysis.There is difference in Immunoscore® results in left- versus right-sided tumors.Total there are 16 patients with left colon cancer with median Immunoscore® -1.94(1,44-2,43).There are 13 patients with right colon cancer with median Immunoscore® -2.23(1,79-2,67).ConclusionThere is association of Immunoscore® and primary tumor sidedness, even in small patients number. We can hypothesize that this could be one of reasons for different prognosis and survival of left and right sided tumors.

This is an open-label, single-arm multicenter stage-2 phase II study investigating the efficacy and safety of 5 fractions of short course radiotherapy, followed by 6 cycles of mFOLFOX-6 plus avelumab, followed by Total Mesorectal Excision (TME), in patients with LARC... Combining both IS and mrTRG achieved a promising predictive value for pCR in LARC and therefore upon further validation may be potentially used for patient selection in non-operative management strategies. Clinical trial information: NCT03503630.